Chronic Administration of the Nitroxyl Donor 1-Nitrosocyclo-Hexyl Acetate Limits Left Ventricular Diastolic Dysfunction in a Mouse Model of Diabetes In Vivo Cao et al: HNO Prevents Diabetic Cardiomyopathy

Chronic administration of the nitroxyl donor 1-nitrosocyclo hexyl acetate limits left ventricular diastolic dysfunction in a mouse model of diabetes mellitus in vivo.

BACKGROUND Nitroxyl (HNO), a redox congener of nitric oxide (NO·), is a novel regulator of cardiovascular function, combining concomitant positive inotropic, lusitropic, and vasodilator properties. Moreover, HNO exhibits myocardial antihypertrophic and superoxide-suppressing actions. Despite these favorable actions, the impact of chronic HNO administration has yet to be reported in the context ...

Vitamin B1 Analogue Benfotiamine Prevents Diabetes-Induced Diastolic Dysfunction and Heart Failure through Akt/Pim-1 Mediated Survival Pathway Katare et al. Benfotiamine prevents diabetic cardiomyopathy

CXL-1020, a Novel Nitroxyl (HNO) Prodrug, Is More Effective than Milrinone in Models of Diastolic Dysfunction—A Cardiovascular Therapeutic: An Efficacy and Safety Study in the Rat

The nitroxyl (HNO) prodrug, CXL-1020, induces vasorelaxation and improves cardiac function in canine models and patients with systolic heart failure (HF). HNO's unique mechanism of action may be applicable to a broader subset of cardiac patients. This study investigated the load-independent safety and efficacy of CXL-1020 in two rodent (rat) models of diastolic heart failure and explored potent...

Nitroxyl (HNO): A novel approach for the acute treatment of heart failure.

BACKGROUND The nitroxyl (HNO) donor, Angeli's salt, exerts positive inotropic, lusitropic, and vasodilator effects in vivo that are cAMP independent. Its clinical usefulness is limited by chemical instability and cogeneration of nitrite which itself has vascular effects. Here, we report on effects of a novel, stable, pure HNO donor (CXL-1020) in isolated myoctyes and intact hearts in experiment...

Diabetic cardiomyopathy.

I t has been over 30 years since Rubler et al. (1) described four diabetic patients with congestive heart failure (CHF), normal coronary arteries, and no other etiologies for CHF and proposed that it was due to diabetic cardiomyopathy. Eight years ago, I reviewed the evidence for diabetic cardiomyopathy as a unique entity unassociated with coronary artery disease and concluded that diabetic car...